Dr. Daniel Thomas Oberlin, MD

Dr. Oberlin practices at Golden Gate Urology Inc in Berkeley, California.

Dr. Oberlin's NPI, 1184910044, was assigned on June 20, 2011. Dr. Oberlin graduated from Cleveland Medical College, Homeopathic in 2011. Dr. Oberlin holds California license A149464.

Dr. Oberlin's primary practice is Golden Gate Urology Inc, at 2999 Regent St, Berkeley, CA 94705 in Alameda County. The practice phone is (415) 543-2830.

Dr. Oberlin's primary practice is Golden Gate Urology Inc in Berkeley, California. Dr. Oberlin is also affiliated with Alta Bates Summit Medical Center | Alta Bates Campus. The medical group on file is Unio Specialty Care, Urology, Encinitas (formerly Genesis Healthcare Partners). Dmand AI also links Dr. Oberlin to 3 more hospitals, 4 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Oberlin practices, 6 sites in all. Vendor and product names are available with a free account.

Urology is Dr. Oberlin's primary specialty in the NPI Registry, under taxonomy code 208800000X. Dr. Oberlin is board certified in urology by the American Board of Urology. Dmand AI has Dr. Oberlin's licenses on file in 2 states: California and Illinois.

Dmand AI lists bladder disease, bladder removal, enlarged prostate, enlarged prostate transurethral surgery (TURP), erectile dysfunction, kidney removal surgery, kidney stone disease and prostate cancer among the conditions Dr. Oberlin treats.

CMS data shows 1,856 Medicare services from Dr. Oberlin across 20 procedure codes in 2024, for 576 Medicare patients. Medicare paid $159,293 for them.

CMS counts 576 Medicare patients who saw Dr. Oberlin in 2024. The largest group is 75 to 84, with 248 patients. 72% of them have high cholesterol, and 71% have high blood pressure. 22% are also on Medicaid. Their average risk score is 1.34, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Oberlin's median patient age at 72, with 15% women.

In 2024, Dr. Oberlin wrote 1,332 Medicare Part D claims for 371 patients. 80% of them were for generic drugs. CMS names the drug for 1,191 of them, across 18 drugs with 11 or more claims each, at $414,945 in total drug cost. In 2023, CMS named 1,163 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Oberlin for performance year 2024, reported as part of a group. Dr. Oberlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Oberlin as offering telehealth. CMS counts 21 procedures of prostate resection by Dr. Oberlin, more than 83% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 29 papers to Dr. Oberlin, published from 2014 to 2018. 2016 was the busiest year, with 10. The most frequent topics are Practice Patterns, Physicians', Urology and Prostatic Neoplasms. Dr. Oberlin has published most often in Urology. Dr. Oberlin's most frequent co-authors are Richard S. Matulewicz, MD, MS, Sarah C. Flury, MD and Laurie Bachrach, MD.

CMS Open Payments shows 416 general payments to Dr. Oberlin from 50 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 62% of the total. Intuitive Surgical, Inc. paid the most, $30,264.

Dmand AI lists 2 awards for Dr. Oberlin, most recently ACS Fellow in 2011.

Dr. Oberlin graduated from Cleveland Medical College, Homeopathic in 2011. Dr. Oberlin is a member of AOA and ACS.

Dr. Oberlin is in network with 14 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.